Hypothyroidism: a growing complication of cancer treatment.
Hypothyroidism is an often underreported complication of cancer treatment. With the growing number of biological and targeted therapies, hypothyroidism may become a more prevalent clinical problem. Signs and symptoms of hypothyroidism may be easily attributed to the cancer or cancer treatment, leading to unnecessary dose modifications or discontinuation of effective therapies. Furthermore, these symptoms have a negative effect on quality of life. Measurement of TSH levels in at-risk patients prior to initiating treatment and at regular intervals during treatment will allow early intervention and effective treatment of hypothyroidism.
Kurtin
Sandra E
SE
University of Arizona, Tuscon, Arizona, USA.
D000911:Antibodies, Monoclonal / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007037:Hypothyroidism / Q000139:chemically induced / Q000188:drug therapy / Q000453:epidemiology*; D015994:Incidence; D007453:Iodide Peroxidase / Q000627:therapeutic use; D000077269:Lenalidomide; D008297:Male; D009369:Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D016499:Radioimmunotherapy / Q000009:adverse effects; D011878:Radiotherapy / Q000009:adverse effects; D013792:Thalidomide / Q000009:adverse effects / Q000031:analogs & derivatives; D014481:United States / Q000453:epidemiology
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D013792:Thalidomide; D007453:Iodide Peroxidase; D000077269:Lenalidomide; C119496:tositumomab I-131